Ifosfamide Side Effects

Ifosfamide is an anti-cancer chemotherapy drug that was first approved by the US Food and Drug Administration in 1988. It is indicated for the treatment of some testicular cancers and some cervical cancers.

Because ifosfamide is so molecularly similar to one of the oldest and most well-understood chemotherapeutics—cyclophosphamide—it has uses against a broad number of different cancers, including brain tumors as well as breast and lung cancers, to name just a few.

The role of ifosfamide in lymphoma treatment is most notable in its use in the combination chemotherapy regimen known as ICE—a preparative regimen for bone marrow transplantations.

Common Side Effects of Ifosfamide

The following side effects are considered to be common side effects of taking Ifosfamide. This list is not inclusive of all side effects, and no patient should expect to experience all of them.

  • Nausea
  • Vomiting
  • Appetite loss
  • Diarrhea
  • Hair loss (temporary)

Serious Side Effects of Ifosfamide

The following serious side effects may occur after receiving any treatment including ifosfamide. If any of these side effects occur, one should seek immediate medical attention:

  • Allergic reactions (this could include a rash, itching, hives, problems breathing, chest tightness, swelling of the mouth, face, lips, or tongue)
  • Frequent, painful or difficult urination
  • Blood in one's urine
  • Stool that is black or tarry in appearance
  • Signs of infection including cough, chills, fever, sore throat
  • Sluggishness, sleepiness, confusion, or hallucinations
  • Unusual bleeding or bruising

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap